Home > Oncology > ASCO GU 2022 > Penile & Testicular Cancer > Atezolizumab does not improve survival in advanced penile cancer

Atezolizumab does not improve survival in advanced penile cancer

Presented By
Dr Hielke-Martijn de Vries, Netherlands Cancer Institute, the Netherlands
Conference
ASCO GU 2022
Trial
Phase 2, PERICLES
The phase 2 PERICLES trial examining atezolizumab with or without radiotherapy in patients with advanced squamous cell carcinoma of the penis missed its primary endpoint of 1-year progression-free survival (PFS) ≥35%. Patients with advanced squamous cell carcinoma of the penis have a poor prognosis and high morbidity, due to progressive locoregional disease [1]. Previous experimental studies in this setting did not prove to be successful [2,3]. Pre-clinical studies show high rates of infiltrating immune cells and high PD-L1 expression, suggesting that immunotherapy may be beneficial for these patients [4]. The single-centre, phase 2 PERICLES trial (NCT03686332) assessed the activity of atezolizumab with or without radiotherapy to control locoregional lymph node disease in patients with advanced squamous cell carcinoma of the penis. The study enrolled 32 pati...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on